Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TIBSOVO vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isocitrate dehydrogenase-2 (IDH2) inhibitor; targets mutant IDH2 isoforms to reduce 2-hydroxyglutarate (2-HG) levels, promoting myeloid differentiation.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
Acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation, relapsed or refractory,Acute myeloid leukemia (AML) with an IDH2 mutation, newly diagnosed in patients ≥75 years or with comorbidities ineligible for intensive induction chemotherapy
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
500 mg orally once daily taken with or without food.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
Terminal elimination half-life: 50-60 hours, supporting once-daily dosing with steady-state reached in approximately 2 weeks.
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Primarily metabolized by CYP3A4; also a minor substrate of CYP2C19, CYP2D6, and UGT1A1.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Primarily hepatic metabolism (CYP3A4) and fecal excretion (77% unchanged and metabolites); renal elimination accounts for <1% of absorbed dose.
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
>99.9% bound, primarily to serum albumin.
Approximately 20–30% bound to plasma proteins.
Volume of distribution (Vd/F): approximately 2.2 L/kg (range 1.7-2.8), indicating extensive extravascular distribution.
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
Estimated absolute bioavailability is approximately 60-70% after oral administration.
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or dialysis.
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
No dose adjustment for mild hepatic impairment (Child-Pugh class A). Moderate or severe hepatic impairment (Child-Pugh class B or C) has not been studied; use with caution and monitor for adverse effects.
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Safety and effectiveness have not been established in pediatric patients; no dosing recommendations available.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
No specific dose adjustment recommended; clinical studies included patients aged 65 years and older, but no overall differences in safety or efficacy were observed compared to younger patients.
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
None
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Differentiation syndrome (can be fatal, treat with corticosteroids and hemodynamic support),QT prolongation (monitor ECG and electrolytes),Embryo-fetal toxicity
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
None known
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
Take on an empty stomach (no food for at least 1 hour before or 2 hours after). Avoid grapefruit and grapefruit juice (CYP3A4 inhibition). High-fat meals significantly increase absorption; avoid concomitant intake.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
Based on animal studies and its mechanism of action (IDH1 inhibition), TIBSOVO (ivosidenib) may cause fetal harm. No adequate human data exist. It is teratogenic in rats at exposures below the clinical dose. Avoid use in pregnancy unless benefit outweighs risk. Confirm negative pregnancy test before initiation. First trimester: risk of major malformations unknown but potential. Second/third trimester: potential for fetal growth restriction and oligohydramnios due to effects on cellular metabolism. Use effective contraception during treatment and for at least 1 month after the last dose.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
No data on presence in human milk, effects on breastfed infants, or milk production. Due to potential for serious adverse reactions, breastfeedin is not recommended during treatment and for at least 1 month after the last dose. M/P ratio not available.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
No formal studies in pregnancy. Dose adjustments for pregnancy-induced physiologic changes (increased plasma volume, renal clearance, hepatic metabolism) are not defined. Standard dosing (500 mg orally once daily) is used; however, close monitoring for toxicity and efficacy is warranted. Use only if clearly needed after consideration of risks.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
TIBSOVO (ivosidenib) is an IDH1 inhibitor indicated for IDH1-mutant acute myeloid leukemia (AML) and cholangiocarcinoma. Monitor for differentiation syndrome, which can be fatal; treat with corticosteroids and hemodynamic support. ECG monitoring for QTc prolongation is required; avoid concomitant use with strong CYP3A4 inhibitors or inducers. Assess liver function before and during therapy. Administer on an empty stomach at least 1 hour before or 2 hours after a meal.
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
Take TIBSOVO on an empty stomach, at least 1 hour before or 2 hours after eating.,Do not crush or chew the tablets; swallow them whole.,Tell your doctor immediately if you experience fever, cough, difficulty breathing, or swelling (signs of differentiation syndrome).,Report any symptoms of heart rhythm changes (dizziness, fainting, chest pain) or liver problems (yellowing skin, dark urine, abdominal pain).,Avoid grapefruit and grapefruit juice during treatment.,Inform all healthcare providers that you are taking TIBSOVO.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
No interactions on record
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TIBSOVO vs CLADRIBINE, answered by our medical review team.
TIBSOVO is a Antineoplastic Agent that works by Isocitrate dehydrogenase-2 (IDH2) inhibitor; targets mutant IDH2 isoforms to reduce 2-hydroxyglutarate (2-HG) levels, promoting myeloid differentiation.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TIBSOVO and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TIBSOVO is: 500 mg orally once daily taken with or without food.. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TIBSOVO and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TIBSOVO is classified as Category C. Based on animal studies and its mechanism of action (IDH1 inhibition), TIBSOVO (ivosidenib) may cause fetal harm. No adequate human data exist. It is teratogenic in rats at exposur. CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.